BriaCell Therapeutics Corp Warrants (24/02/2025) BCTXW 深 滬
等待開盤 11-26 09:30:00 美东时间
0.0418
0.000
0.00%
華盛通- 最 高0.00
- 今 開0.0418
- 成交量 10股
- 最 低 0.00
- 昨 收 0.0418
- 總市值 31.50万
- 52周最高 0.70
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.0113
- 委 比 98.02%
- 總股本 753.67万
- 歷史最高 7.04
- 量 比 0.00
- 振 幅 0.00%
- 歷史最低 0.0113
- 每 手 1
- 風險率 0.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BriaCell Therapeutics Announces Clinical Biomarker Data In Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus An Immune CPI In Metastatic Breast Cancer
Biomarkers identified in BriaCell's Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC)No new safety or tolerability issues
10-20 19:33
BriaCell to Present Phase 3 Biomarker Data for Bria-IMT in Metastatic Breast Cancer at ESMO 2025
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, will be presenting
10-13 19:34
BriaCell Therapeutics To Present Preclinical Bria-OTS+ Data At SITC Annual Meeting
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to
10-03 19:37
BriaCell Publishes Breakthrough Cancer Immunotherapy Research In JCI Insight Journal
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the
08-26 19:35
BriaCell Announces 1-for-10 Share Consolidation To Maintain Nasdaq Listing, Effective August 25, 2025
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that
08-22 00:02
BriaCell Joins MSK's 2025 Therapeutics Accelerator to Fast-Track Cancer Immunotherapy
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to
08-13 19:36
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
BriaCell Therapeutics Corp. announced its acceptance into Memorial Sloan Kettering Cancer Center’s 2025 Therapeutics Accelerator program to accelerate the clinical development of its Bria-OTS+ immunotherapy for multiple cancers, including breast and prostate cancer. MSK’s resources will support regulatory and manufacturing efforts, with both parties expressing confidence in the therapy’s potential to advance cancer care.
08-13 11:30
BriaCell Unveils TILsRx Platform Aiming To Supercharge Immune Response Against Hard-To-Treat Cancers
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))), (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary,
07-29 19:34
BriaCell Therapeutics Announces Closing of $15 million Public Offering
BriaCell Therapeutics Corp. has completed a best-efforts public offering of 12 million units, raising $15 million gross proceeds. Each unit includes one common share or a pre-funded warrant and one warrant. The pre-funded warrants are exercisable at $0.001, while the warrants are exercisable at $1.50 per share for five years. The company intends to use the net proceeds for working capital, general corporate purposes, and advancing business object...
07-16 20:05
BriaCell Therapeutics Reports Updated Results From Ongoing Phase 2 Study Of Bria-IMT In Combination With Check Point Inhibitor In Patients With Advanced Metastatic Breast Cancer
Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of treatment"Eye bulging" metastatic breast cancer patient had failed 8 prior regimens, including
07-10 19:34
